Sanofi (France)
NEWS
Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.
Recently, a few companies and government programs have decided to enact their own plans that they believe will help bring down the cost of new therapies. Pharmaceutical companies have begun asserting their positions on the topic.
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.
Days after selling future royalty streams for two Sanofi diabetes drugs for $205 million, Denmark-based Zealand Pharma announced its Phase III trial for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints that sets up potential regulatory approval.
Paris-based Sanofi announced it is refocusing two of its international business units. The goal is to create more focus on mature markets and emerging markets.
Amicus Therapeutics, headquartered in Cranbury, New Jersey, held a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding its regulatory path for AT-GAA for Pompe Disease. The company released its plans for the drug.
Let’s take a look at who made a splash in the pharma and biotech world the past week.
Copenhagen-based Zealand Pharma is selling future royalty streams and $85 million in potential commercial milestones for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma.
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
JOBS
IN THE PRESS
